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Abstract 
Septic complications have been major problems in the management of patients with obstructive jaundice and neonatal jaundice. This 
study investigates ffects of bilirubin on human T lymphocyte r sponses against allogeneic mixed lymphocyte r action. In vitro exposure 
of human peripheral blood mononuclear cells (PBMNC) with unconjugated bilimbin at pathological levels (6 to 12 mg/dl) did not alter 
the subsets of CD3, CD4, CD8, CD14, CD19 and CD56 positive populations, or expression of costimulatory surface molecules CD2, 
CD3, CD4 and CD8. Further incubation of bilirubin-treated PBMNC with irradiated B lymphoid Raji cells after removal of the 
extraceilular bilirubin resulted in a dose-dependent decrease of cytotoxic T lymphocyte (CTL) activity, DNA synthesis, and expression of 
Tac antigen (CD25) and transferrin receptor (CD71). However, no significant change of interleukin-2 (IL-2) production was observed 
after this incubation between bilirubin-treated and -untreated PBMNC. These results uggest that bilirubin inhibits the induction of CTL 
activity, and this defect may result from the impaired responsiveness against IL-2. These observations may help explain the increased 
infection observed in hyperbilirubinemic patients. 
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1. Introduction 
Sepsis is a major complication leading to the high 
mortality in patients with obstructive jaundice and neonatal 
jaundice [1,2]. However, the mechanisms for this increased 
susceptibility to infection have not been fully understood. 
We previously demonstrated that mitogen-induced produc- 
tion of interleukin-1 and interleukin-2 (IL-2) by peripheral 
blood mononuclear cells (PBMNC) was impaired in pa- 
tients with obstructive jaundice and that this defect im- 
proved after external biliary drainage [3]. Unconjugated 
bilirubin is known to inhibit key enzymes in various 
cellular functions [4]. Desmet et al. [5] demonstrated that 
both unconjugated and conjugated bilirubin were deposited 
in the cytoplasm of infiltrating mononuclear leukocytes 
and Kupffer cells, as well as hepatocytes of the liver tissue 
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in patients with obstructive jaundice. We have also demon- 
strated that unconjugated bilirubin may be incorporated 
into human lymphocytes and monocytes via different en- 
ergy-dependent mechanisms [6]. These findings suggest 
that bilirubin compounds may, at least in part, be responsi- 
ble for the decreased immune responses in jaundiced pa- 
tients. 
T lymphocytes play an important role in host defense 
system against microorganisms [7]. It is known that immu- 
nized T cells of intestines can migrate to the lung and 
respond to eliminate bacteria [8]. CD4-positive T cells 
respond to class II major histocompatibility (MHC) anti- 
gen, while CD8-positive T cells to class I antigen. MHC 
class II antigen is mainly implicated in the proliferative 
allogeneic stimulation and lymphokine release. Class I 
antigens activate cytotoxic T lymphocyte (CTL) precursors 
to a state of responsiveness to soluble mediators [9]. Cell 
surface antigens, CD2, CD3, CD4, CD8, LFA-1 and Tp 
103 expressed on T cells, are involved in T cell-target cell 
interaction or T cell activation. After exposure to foreign 
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MHC determinants, T cells proliferate and acquire cy- 
tolytic capacity toward cells bearing the specific sensitiz- 
ing alloantigen. IL-2 plays a major role in the growth and 
differentiation of CTL precursors and in CTL proliferation 
[101. 
This study was undertaken to investigate in vitro effects 
of unconjugated bilirubin on allogeneic T lymphocyte 
responses against human B lymphoid cell line 'Raji' cells 
which express both class I and class II MHC molecules 
[11]. 
2. Mater ia l s  and  methods  
All immunological experiments were performed with 
viability of PBMNC greater than 95% as determined by 
trypan blue dye exclusion. 
2.1. Medium and buffers 
1. BSA/PBS: 3.0 g/dl  bovine serum albumin (BSA) 
(Fraction V, Sigma, St. Louis, MO, USA) dissolved in 
l0 mmol/ l  sodium phosphate (pH 7.4), 0.15 mol/1 
NaC1 (PBS). 
2. PBS/BCS/NaN3: PBS containing 2% (v/v)  bovine 
calf serum supplemented (BCS) (Hyclone Laboratories, 
Logan, UT, USA) and 1.0 g / l  sodium azide. 
3. CM-10 medium: RPMI-1640 medium supplemented 
with 10% (v/v)  BCS, 50/xg/ml  gentamycin (Sigma), 
25 mmol/1 Hepes (Sigma), 1 × minimal essential 
medium amino acids (Hazleton Biologics, Lenexa, KS, 
USA). 
2.2. Bilirubin treatment of human PBMNC 
Human PBMNC were separated from venous blood of 
healthy donors by the density gradient of lymphocyte 
separating media as described before [6]. Bilirubin treat- 
ment of freshly-isolated human PBMNC was carded out at 
37°C for 60 min at 5.106 cells/ml in the presence or 
absence of bilirubin IX a, a major isoform of unconjugated 
bilirubin (Sigma) at 6 to 12 mg/dl  in BSA/PBS as 
described before [6]. The levels of bilirubin and albumin 
used in the current experiments were comparable to the 
serum levels observed in hyperbilirubinemic patients. 
2.3. CTL generated from allogeneic MLR 
Allogeneic mixed lymphocyte reaction (MLR) was per- 
formed as described before [12]. Bilirubin-untreated or
-treated PBMNC were resuspended at 5. 10 6 cells/ml in 
CM-10 (Responder cells). Raji cells, human B cell Burkitt 
lymphoma cell line, were y-irradiated (5 kRad) and resus- 
pended at 7.5.105 cells/ml in CM-10 (stimulator cells). 
1.0 ml of the responder cell suspension and 1.0 ml of the 
stimulator cell suspension were added into a well in dupli- 
cate of a 24-well microplate (Coming Glass, Coming, NY, 
USA). The plates were incubated at 37°C for 96 h in a 
humidified atmosphere of 5% CO 2. In some experiments, 
mouse anti-human IL-2R /3 chain monoclonal antibody, 
TU27 [13], was added in the culture to measure the real 
production of IL-2 in superuatant by avoiding the possible 
effect of decreased IL-2 utilization in bilirubin-treated 
PBMNC with MLR. After the incubation, the culture 
supernatant and the non-adherent cells were collected after 
the centrifugation at250 × g for 15 min. The IL-2 activity 
in the supernatant (IL-2 production) was measured by a 
CTLL-2 assay. The cells were washed once with PBS, and 
used for effector cells of CTL assay, or analyzed by a 
direct immunofluorescence assay. The viability of biliru- 
bin-untreated and -treated PBMNC was greater than 95% 
after the 96 h MLR culture. 
2.4. CTL cytotoxic assay 
CTL assay was performed by a 4 h chromium-release 
assay as described before [12]. Briefly, non-adherent cells 
recovered from MLR were incubated at 37°C for 4 h with 
5. 10 3 cells of 51Cr-labeled Raji cells at effector/target 
ratio 50, 25, 12 and 6 in 300 /xl of CM-10 in a well of 
96-well round bottom microplate (Coming) in quadrupli- 
cate. Control wells, for spontaneous release and maximal 
release from target cells, contained CM-10 medium and 
dilute detergent, respectively. After the incubation, 200/xl 
of cell free supernatants were harvested from each well, 
and the radioactivity was measured by a gamma-counter. 
Specific chromium release (%) was calculated as (experi- 
mental release - spontaneous release) - (maximal release 
- spontaneous release) × 100. The lytic unit at 20% killing 
(LU20) conversion was done by an exponential-fit method 
of analysis, which allows comparison of the lytic activities 
of different effector populations [12]. 
2.5. Measurement of lymphocyte proliferation in MLR 
DNA synthesis of PBMNC was estimated by 
[3H]thymidine uptake as described before [12]. Briefly, 
following to the bilirubin-treatment, 2.105 cells of biliru- 
bin-untreated or -treated PBMNC were incubated at 37°C 
for 96 h in a 5% CO 2 incubator with 3. 10 4 cells of 
"y-irradiated Raji cells in 200 /zl of CM-10 in a well of 
96-well flat-bottom plates (Coming) in quadruplicate. The 
cells were pulsed with 0.5 /xCi/well of [3H]thymidine for 
the final 4 h of the incubation and harvested onto a glass 
fiber filter sheet by a semiautomatic cell harvester. The 
radioactivity trapped on the harvesting filters was mea- 
sured in a liquid scintillation counter. 
2.6. IL-2 assay 
IL-2 activity was measured by the CTLL-2 proliferation 
assay according to Gillis et al. [14]. CTLL-2 cells in 
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growing phase were harvested, incubated at 37°C for 60 
min in RPMI-1640 medium to remove endogenous IL-2, 
washed once with RPMI-1640 medium and resuspended at
5 • 105 cel ls/ml in CM-10. 100/zl of the CTLL-2 suspen- 
sion were added to each well of 96-well flat-bottom mi- 
croplates in quadruplicate with 100 /xl of serial dilutions 
of test IL-2 samples, standard IL-2 (human recombinant 
1L-2, Cetus, Emeryville, CA, USA), or media only for the 
negative control. The cells were incubated at 37°C for 18 h 
in a 5% CO 2 incubator, pulsed with 0.5 /xCi/well of 
[3H]thymidine for an additional 4 h, and harvested. The 
uptake of [3H]thymidine by IL-2-boosted cells was quanti- 
fied by a scintillation counter and the titer of IL-2 was 
expressed by probit analysis. The activity of IL-2 ( IU/ml)  
in test samples was determined by comparing their activi- 
ties with the activity of the standard IL-2 sample run in 
every assay. Even after the extensive washes of bilirubin- 
treated PBMNC, these cells release intracellular bilirubin 
into the culture supernate during the 96 h MLR. The 
concentrations of bilirubin remaining in the supernatants 
were proportional to the bilirubin doses to treat cells, but 
the levels were quite low (less than 0.6 mg/dl ,  Fig. 1A). 
These modest levels of bilirubin do not interfere with the 
biologic response of CTLL-2 cells (Fig. 1B). 
2.7. Analysis of expression of cell surface antigens 
Expression of CD2, CD3, CD4, CD8, CD14, CD19, 
CD56, Tac antigen (CD25) and transferrin receptor (TfR; 
CD71) on lymphocyte fraction was analyzed by a direct 
immunofluorescence m thod using a flow cytometry FAC- 
Scan (Becton-Dickinson, lmmunocytometry systems, 
Mountainview, CA, USA) as described before [15]. All 
mouse monoclonal antibodies (FITC-labeled) against hese 
antigens and control antibodies were purchased from Bec- 
ton-Dickinson. Amounts of the antigen expressed on a cell 
were estimated by the difference between the mean intensi- 
ties of the FL 1 fluorescence for the antibody directed and 
for the control antibody, as described before [16]. 
2.8. Statistical analysis 
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Fig. 1. Effect of bilirubin on biological CTLL-2 proliferation assay. (A) 
Concentrations of bilirubin released into the culture supernatants of MLR. 
Freshly-isolated PBMNC were treated at 37°C for 60 rain with 0 to 12 
mg/dl of bilirubin, washed three times, and incubated at37°C for 96 h 
with irradiated Raji cells (MLR) as described inSection 2. The levels of 
bilirubin in the supernatants were measured. (B) Effect of bilirubin on 
CTLL-2 assay. IL-2 dependent cell line, CTLL-2, was cultured at 37°C 
for 22 h with serially diluted human recombinant IL-2 (rIL-2) in the 
presence or absence of the above final concentrations of bilirubin as 
described in Section 2. [3H]Thymidine uptake was quantified by a liquid 
scintillation counter. 
Statistical significance was analyzed by the Student's 
t-test for paired samples. 
3. Results 
3.1. Effect of bilirubin on expression of cell surface anti- 
gen 
Our previous study [6] demonstrated that in vitro expo- 
sure of human PBMNC to bilirubin at 0 to 12 mg/d l  
resulted in a dose-dependent increase of intracellular 
bilirubin (0 to 4 or 6 .10-15  mol/cell). The subsets of cell 
surface markers in bilirubin-treated PBMNC were un- 
changed when compared with bilirubin-untreated PBMNC 
(normal values of CD14 for monocytes, 11.3 _ 5.7%; CD3 
for whole T cells, 65.3 _ 8.1%; CD4 helper T cells, 38.5 
+ 6.5%; CD8 cytotoxic T cells, 27.6 _ 7.5%; CD19 for B 
cells, 9.8 + 3.8%; CD56 for NK cells, 10.7 + 5.2%). Sub- 
sequently, we studied the amounts of cell surface antigens 
CD2, CD3, CD4, and CD8, which are involved in CTL-  
target cell interaction and T cell activation [9]. Similarly, 
the amounts of these antigens expressed on the bilirubin- 
treated PBMNC were also unchanged as compared to 
bilirubin-free control cells (normal values (arbitrary units) 
of CD2, 59.0 _ 7.9; CD3, 66.1 + 10.I; CD4, 11.5 + 1.0; 
CD8, 242 ___ 54.5). 
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Table 1 
Effect of bilirubin on CTL activity, DNA synthesis and IL-2 production of PBMNC after allogeneic MLR 
Bilirubin dose Raji CTL activity [3H]Thymidine IL-2 production 
(mg/dl)  cells (LU20) uptake (cpm) ( IU/ml) 
0 ( - )  0.83 ± 0.33 1246 ± 702 5.1 ± 8.3 
0 (+)  14.3 ±8.0 16730+ 8976 175 + 175 
6 (+)  12.7 ±9.8 12460± 8206 200+ 118 
8 (+)  7.6 ±8.3 " 6560+4146 * 219±123 
10 (+)  2.1 +2.2 ** 2790± 812 ** 246± 140 
12 (+)  0.85±0.72 *** 1508± 596 *** 173± 113 
Freshly-isolated PBMNC were treated with bilirubin at 0 to 12 mg/d l  in BSA solution. The cells were washed and further incubated for 96 h in the 
absence or presence of irradiated B lymphoid Raji cells (MLR). The cells were evaluated for CTL activity against Raji cells by a chromium-release assay 
(n = 8). IL-2 activity of the MLR supernatant was measured by a CTLL-2 proliferation assay (n = 8). In another set of experiments, the cells were pulsed 
with [3H]thymidine for the final 4 h of the MLR, and the radioactivity was estimated by a liquid scintillation counter (n = 9). Data represent a
mean ± S.D. of healthy donors. Statistical significance was evaluated by comparing each data point of bilirubin-untreated cells with irradiated Raji cells. 
* P< 0 .05 ,  * * P<0.01 ,  * * * P <0.001 .  
3.2. CTL activity, proliferation and IL-2 production of 
bilirubin-treated PBMNC in allogeneic MLR 
Bilirubin-untreated and -treated PBMNC were cultured 
for 96 h with irradiated B lymphoid Raji cells and assayed 
for cytotoxic activity against Raji cells (CTL activity), 
DNA synthesis, and IL-2 production (Table 1). T cells are 
primarily responsible for these responses [12]. Bilirubin- 
treated PBMNC in the MLR showed a dose-dependent 
decrease of CTL activity. Similarly, bilirubin-treated 
PBMNC after the MLR showed a dose-dependent decrease 
of DNA synthesis. However, bilirubin-treated PBMNC in 
the MLR produced equal or even enhanced levels of IL-2 
as compared to bilirubin-untreated cells. To avoid the 
possible effect of decreased IL-2 utilization in bilirubin- 
treated PBMNC, IL-2 levels in the supernatants were 
measured after the MLR co-cultured with or without anti- 
IL-2R fl chain: TU27 (Fig. 2). TU27 increased the IL-2 
level of supernatant in bilirubin-untreated PBMNC by 
43%. IL-2 levels in bilirubin-treated PBMNC with TU27 
were unchanged to the bilirubin-free control level. In 
contrast, a slight increase of IL-2 was observed in PBMNC 
treated at 8 or 10 mg/dl of bilirubin without TU27. 
Therefore, the slight increase (about 30%) of IL-2 in the 
supernatants in bilirubin-treated PBMNC with MLR may 
result from the decrease of IL-2 utilization. 
3.3. Expression of Tac Ag and TfR in bilirubin-treated 
PBMNC in allogeneic MLR 
Expression of activation antigens Tac and TfR was 
studied on bilirubin-treated PBMNC after allogeneic MLR 
(Table 2). In bilirubin-untreated PBMNC, the MLR en- 
hanced the expression of both antigens (4.6-fold for Tac 
and 3.3-fold for TfR as compared to the cells without he 
MLR). In bilirubin-treated PBMNC, expression of both 
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Fig. 2. Effect of anti-IL-2R antibody on IL-2 levels in MLR supernatants 
of bilirubin-treated PBMNC. Freshly-isolated PBMNC were treated at 
37°C for 60 min with 0 to 12 mg/d l  of bilirubin, washed three times, and 
incubated at 37°C for 96 h with irradiated Raji cells (MLR) with or 
without anti-IL-2R /3 chain (TU27) as described in Section 2. IL-2 levels 
in the supernatants were measured by a CTLL-2 proliferation assay. 
Table 2 
Effect of bilirubin on 
after allogeneic MLR 
Bilirubin Raji 
dose cells 
(mg/dl)  
expression of Tac antigen (CD25) and TfR (CD71) 
Amounts of cell surface antigens 
(arbitrary units) 
Tac antigen TfR 
0 ( - )  6.1± 1.8 4.5±2.2 
0 (+)  28.1±10.8 15.0±7.1 
6 (+)  27.8±11.7 13.0±5.3 
8 (+)  20.1± 9.8 11.1±6.3 
10 (+)  10.3± 6.1"*  6 .6±4.5*  
12 (+)  5.4± 3.0**  3 .7±2.5*  
Freshly-isolated PBMNC were treated with bilirubin at 0 to 12 mg/d l  in 
BSA solution. The cells were washed and further incubated in the 
absence or presence of irradiated B lymphoid Raji cells (MLR). Amounts 
of Tac antigen or TfR on bilirubin-treated lymphocytes were evaluated by 
a flow cytometry. Data represents a mean _+ S.D. of six donors. Statistical 
significance was evaluated by comparing each data point of bilirubin-un- 
treated cells with irradiated Raji cells. * P < 0.05, * * P < 0.01. 
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Table 3 
Summary of in vitro bilirubin studies 
Donor Cell Bilirubin Stimulus DNA IL-2 Tac or TfR Cytotoxic 
population treatment synthesis production expression activity 
1. Jaundiced patients PBMNC ( - ) Con A N.D. decreased N.D. N.D. 
2. Healthy PBMNC ( + ) PHA decreased decreased unchanged N.D. 
3. Healthy PBL ( + ) ( - ) N.D. N.D. N.D. NK, ADCC decreased 
3. Healthy PBL ( + ) IL-2 decreased N.D. unchanged LAK, ADCC decreased 
4. Healthy PBMNC ( + ) MLR decreased unchanged decreased CTL decreased 
1. Ref. [3]; 2. Ref. [17]; 3. Ref. [18]; 4. Present study. Abbreviations: TfR, transferrin receptor; PBMNC, peripheral blood mononuclear cells; Con A, 
concanavalin A; N.D., not done; PBL, peripheral blood lymphocytes; NK, natural killer; ADCC, antibody dependent cellular cytotoxicity; LAK, 
lymphokine activated killer; MLR, mixed lymphocyte reaction; CTL, cytotoxic T lymphocyte. 
antigens after the MLR decreased in a dose-dependent 
manner. 
4. Discussion 
It is now widely accepted that T cell-dependent immune 
responses may be polarized by the activation of different 
CD4-positive helper T cells. Thl cells secrete IL-2 and 
interferon-y, and predominate in cell-mediated immunity, 
particularly during intracellular infections (e.g. protozoa, 
bacteria, viruses). Conversely, Th2 cells produce IL-4, 
IL-5, IL-6, IL-9 and IL-10, which help antibody produc- 
tion, and play a prominent role in anti-helminth and aller- 
gic responses [5]. IL-2 plays a major role in the growth and 
differentiation of CTL precursors and proliferation of CTL 
[10]. The present study clearly demonstrates that unconju- 
gated bilirubin at pathological levels inhibits in vitro CTL 
activity and proliferative responses of human PBMNC in 
allogeneic MLR. This inhibition did not result from the 
alteration of cell populations or expression of costimula- 
tory molecules, CD2, CD3, CD4 and CD8. Although 
bilirubin inhibits CTL or proliferative response in the 
MLR, IL-2 production was not inhibited in these cells. 
Furthermore, the expression of Tac antigen and TfR was 
impaired in bilirubin-treated lymphocytes after the MLR, 
induction of which was dependent on the binding of IL-2 
to its high affinity receptors. These results suggest hat 
expression of high affinity IL-2 receptors, binding of IL-2 
to its high affinity receptors, or the subsequent signal 
transduction may be impaired in bilirubin-treated lympho- 
cytes. 
Our previous data revealed that incubation of bilirubin- 
treated PBMNC with phytohemagglutinin A (PHA) re- 
sulted in a decrease of DNA synthesis and IL-2 production 
without significant change of expression of Tac antigen 
and TfR [17]. The discrepancy between the current data 
and those experiments may be due to the difference of 
stimulation methods. PHA primarily induces T cell prolif- 
eration but not any cytolytic activity. Although the 
[3H]thymidine uptake by the PHA-induced PBMNC was 
higher than that of the current study, the IL-2 production 
was much lower than the current study. In another experi- 
ment, we have demonstrated that unconjugated bilirubin 
also inhibits in vitro MHC-unrestricted cytotoxicity and 
proliferative response against IL-2 in human lymphocytes 
[ 18]. These data are summarized in Table 3. Among these 
different stimulations, proliferative responses and cytolytic 
activities were usually inhibited in bilirubin-treated lym- 
phocytes. Further studies are now under way regarding the 
mechanistic view of effects of unconjugated bilirubin on 
lymphocyte function. 
In summary, unconjugated bilirubin inhibits CTL activ- 
ity and proliferative response in allogeneic MLR at the 
levels observed in patients with obstructive jaundice and 
neonatal jaundice. These results may help explain the poor 
prognosis of these patients when complicated with infec- 
tions. 
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